Non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is a major biological and clinical category of lung cancer that is investigated through its histologic, molecular, and treatment-response characteristics.
Non-small cell lung cancer (NSCLC) is a major biological and clinical category of lung cancer that is investigated through its histologic, molecular, and treatment-response characteristics. Recent work has focused on adenocarcinoma and adenocarcinoma of the lung, actionable alterations involving the EGFR, and less common molecular contexts such as NRAS-mutant disease. Molecular profiling approaches include massively parallel sequencing, proteomics, and analysis of small bronchoscopic tumor specimens.
NSCLC research also encompasses systemic and targeted therapies, including epidermal growth factor receptor tyrosine kinase inhibitors and other tyrosine-kinase inhibitors such as osimertinib and lazertinib, as well as immune checkpoint inhibitors directed toward pathways involving the CD274 molecule. Important clinical measures include objective response rate, progression-free survival, and overall survival. Other active areas include central nervous system involvement, tumor microenvironment biology, drug delivery, cytotoxicity, and apoptosis.
Where the papers sit
26 papers from the last 6 months study non-small cell lung cancer directly · updated from PubMed 1 Nov 2026
Study type 1 clinical trial · 11 observational · 4 human data · 4 preclinical · 6 unclassified
Themes one subject
Those 26 are all about one subject.
-
Lung Cancer Clinical Management
Clinical management is broadening from diagnosis and resection to molecularly guided systemic therapy and brain-metastasis care. Biomarker testing in cytology and small bronchoscopic specimens, imaging-based prediction, and serial ctDNA monitoring support earlier classification and detection of resistance. EGFR-directed treatment, including osimertinib and lazertinib, remains central, while pembrolizumab and ABCP therapy address selected advanced disease. Real-world outcomes, treatment adoption, recurrence definitions, surgery, and immune-related adverse events remain active areas without a single dominant direction.
Papers
The 26 papers from the last 6 months that study non-small cell lung cancer directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Lung Cancer Clinical Management (26)
- Preanalytical variables affect predictive immunohistochemical biomarker testing in non-small cell lung carcinoma cytology specimens. Cancer cytopathology · 9 Oct 2026 PMID 42851084
- Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management. Journal of neuro-oncology · 5 Oct 2026 PMID 42831966
- Clinical Outcomes and Prognostic Factors of ABCP Therapy in EGFR-mutated NSCLC in the Osimertinib Era. Anticancer research · 1 Oct 2026 PMID 42823148
- Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2-Negative Breast Cancer: A Real-World Study. Cancer medicine · 1 Oct 2026 PMID 42817873
- Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 23 Sept 2026 PMID 42778497
- FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland. Acta oncologica (Stockholm, Sweden) · 23 Sept 2026 PMID 42776017
- National trends, variation and short-term outcomes in surgery for non-small cell lung cancer in England, 2015-2023: a population-based cohort study using linked national cancer registration and hospital administrative data. BMJ open · 16 Sept 2026 PMID 42749376
- Defining Early Recurrence in Resectable Non-small Cell Lung Cancer Using Post-Recurrence Survival. Lung · 16 Sept 2026 PMID 42747627
- Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01. Thoracic cancer · 31 Aug 2026 PMID 42670582
- Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States. Lung cancer (Amsterdam, Netherlands) · 24 Aug 2026 PMID 42636546
- Anti-NSCLC mechanism of Inonotus obliquus polysaccharides unveiled by integrated metabolomics and proteomics. International journal of biological macromolecules · 30 Jul 2026 PMID 42532236
- Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens. NPJ precision oncology · 27 Jul 2026 PMID 42509268
- Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer. Drugs - real world outcomes · 23 Jul 2026 PMID 42489799
- Long-term survival of lung cancer despite neurofibromatosis type 1-associated diffuse lung disease. BMJ case reports · 21 Jul 2026 PMID 42481140
- Recurrent lung cancer with multi-organ metastases showing remarkable regression after two weeks of targeted therapy: a case report. Journal of cardiothoracic surgery · 29 Jun 2026 PMID 42374440
- [Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 26 Jun 2026 PMID 42362407
- Scenario-based multi-parametric QC for quality control of complex algorithms used in clinical care. Clinical chemistry and laboratory medicine · 20 Jun 2026 PMID 42321983
- Nanomedicine in 2026: Illustrative Quantitative Analyses of EPR Heterogeneity, Clinical Trial Attrition, and Emerging Horizons for Active Nanotherapeutics. International journal of nanomedicine · 18 Jun 2026 PMID 42311422
- p40-engineered CAR T-cells targeting CD276 enhance anti-tumor efficacy in non-small cell lung cancer. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262195
- Clonal lineage tracing of innate immune cells in human cancer. Cancer cell · 4 Jun 2026 PMID 42242233
- Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
- Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. Lung cancer (Amsterdam, Netherlands) · 29 May 2026 PMID 42214243
- Local control and dose selection for lung cancer brain metastases treated with radiosurgery: an artificial intelligence model. Clinical & experimental metastasis · 26 May 2026 PMID 42189324
- The global landscape of TIGIT-targeted cancer clinical trials: Trends, geographic shift, and policy implications. Journal of cancer policy · 16 May 2026 PMID 42142605
- Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer. Journal of neuro-oncology · 15 May 2026 PMID 42141140
- Piperlongumine inhibits the proliferation and migration of non-small cell lung cancer cells through the EGFR/FAK/STAT3 pathway. Molecular biology reports · 14 May 2026 PMID 42133146
By study type
Clinical trials (1)
- Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. Lung cancer (Amsterdam, Netherlands) · 29 May 2026 PMID 42214243
Observational studies and case reports (11)
- Preanalytical variables affect predictive immunohistochemical biomarker testing in non-small cell lung carcinoma cytology specimens. Cancer cytopathology · 9 Oct 2026 PMID 42851084
- Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management. Journal of neuro-oncology · 5 Oct 2026 PMID 42831966
- Clinical Outcomes and Prognostic Factors of ABCP Therapy in EGFR-mutated NSCLC in the Osimertinib Era. Anticancer research · 1 Oct 2026 PMID 42823148
- Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2-Negative Breast Cancer: A Real-World Study. Cancer medicine · 1 Oct 2026 PMID 42817873
- FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland. Acta oncologica (Stockholm, Sweden) · 23 Sept 2026 PMID 42776017
- National trends, variation and short-term outcomes in surgery for non-small cell lung cancer in England, 2015-2023: a population-based cohort study using linked national cancer registration and hospital administrative data. BMJ open · 16 Sept 2026 PMID 42749376
- Defining Early Recurrence in Resectable Non-small Cell Lung Cancer Using Post-Recurrence Survival. Lung · 16 Sept 2026 PMID 42747627
- Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States. Lung cancer (Amsterdam, Netherlands) · 24 Aug 2026 PMID 42636546
- Long-term survival of lung cancer despite neurofibromatosis type 1-associated diffuse lung disease. BMJ case reports · 21 Jul 2026 PMID 42481140
- Recurrent lung cancer with multi-organ metastases showing remarkable regression after two weeks of targeted therapy: a case report. Journal of cardiothoracic surgery · 29 Jun 2026 PMID 42374440
- Local control and dose selection for lung cancer brain metastases treated with radiosurgery: an artificial intelligence model. Clinical & experimental metastasis · 26 May 2026 PMID 42189324
Human data, design not indexed (4)
- Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01. Thoracic cancer · 31 Aug 2026 PMID 42670582
- Scenario-based multi-parametric QC for quality control of complex algorithms used in clinical care. Clinical chemistry and laboratory medicine · 20 Jun 2026 PMID 42321983
- The global landscape of TIGIT-targeted cancer clinical trials: Trends, geographic shift, and policy implications. Journal of cancer policy · 16 May 2026 PMID 42142605
- Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer. Journal of neuro-oncology · 15 May 2026 PMID 42141140
Preclinical: animal, cell and lab studies (4)
- Nanomedicine in 2026: Illustrative Quantitative Analyses of EPR Heterogeneity, Clinical Trial Attrition, and Emerging Horizons for Active Nanotherapeutics. International journal of nanomedicine · 18 Jun 2026 PMID 42311422
- p40-engineered CAR T-cells targeting CD276 enhance anti-tumor efficacy in non-small cell lung cancer. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262195
- Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
- Piperlongumine inhibits the proliferation and migration of non-small cell lung cancer cells through the EGFR/FAK/STAT3 pathway. Molecular biology reports · 14 May 2026 PMID 42133146
Unclassified: not yet indexed with MeSH (6)
- Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 23 Sept 2026 PMID 42778497
- Anti-NSCLC mechanism of Inonotus obliquus polysaccharides unveiled by integrated metabolomics and proteomics. International journal of biological macromolecules · 30 Jul 2026 PMID 42532236
- Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens. NPJ precision oncology · 27 Jul 2026 PMID 42509268
- Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer. Drugs - real world outcomes · 23 Jul 2026 PMID 42489799
- [Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 26 Jun 2026 PMID 42362407
- Clonal lineage tracing of innate immune cells in human cancer. Cancer cell · 4 Jun 2026 PMID 42242233
Written from 26 PubMed abstracts, each one listed by PMID above. Published: 2026-09-02. Last written: 2026-09-25 by GPT. Drafted by language models from published abstracts; not medical advice.